Biopharma
ByBioNextAI Media Report: Merck’s Gardasil Cuts—$200M Savings, 150 Layoffs Amid 5-10% Demand Drop
Published by BioNextAI Media – In a calculated response to softening markets, Merck is halting production of its HPV…
Merck’s Bold Pivot: Can Dividing Oncology from the Rest Save Keytruda’s Legacy?
Merck’s audacious restructuring of its pharmaceutical operations into standalone oncology and non-oncology divisions isn’t mere corporate tinkering—it’s a…
Is Bayer’s Lawsuit Against Johnson & Johnson Escalating the Competitive Battle in Prostate Cancer Therapeutics?
Leverkusen, Germany — Bayer AG has filed a lawsuit in U.S. federal court against Johnson & Johnson, alleging…
Is Johnson & Johnson’s $1 Billion Pennsylvania Investment a Defining Bet on the Future of Cell Therapy?
New Brunswick, N.J. — Johnson & Johnson today announced plans to invest more than $1 billion to construct…
What Drives Novartis’ Pipeline Dominance Through 2030?
Novartis’ clinical pipeline exemplifies a “focus factory” strategy, ruthlessly prioritizing 30+ high-ROI NMEs across five core areas (immunology,…
Is CMS’s Block on Elevance MA Sign‑Ups a Turning Point for Payer Compliance?
The Centers for Medicare & Medicaid Services (CMS) has halted new Medicare Advantage enrollments for Elevance Health, freezing sign‑ups for…
